Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 95 12-1 Month Momentum % is 18.87% as of Sep. 08, 2026. GuruFocus rates BSP:RADL3 with a GF Score™ of 95/100 and a GF Value™ of R$27.42 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 656 Healthcare Providers & Services companies, Raia Drogasil ranks better than 81.25% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-08), Raia Drogasil's 12-1 Month Momentum % is 18.87%.
The industry rank for Raia Drogasil's 12-1 Month Momentum % or its related term are showing as below:
BSP:RADL3's 12-1 Month Momentum % is ranked better than 81.25% of 656
companies
in the Healthcare Providers & Services industry
Industry Median: -12.46
vs BSP:RADL3: 18.87
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil 12-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a 12-1 Month Momentum % of 18.87% as of Sep. 08, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Raia Drogasil and its competitors. According to the industry distribution chart, Raia Drogasil ranks #123 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 18.7%.
Is Raia Drogasil's 12-1 Month Momentum % too high?
Raia Drogasil's current 12-1 Month Momentum % is 18.87%. Based on the distribution chart, Raia Drogasil ranks #123 out of 656 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Raia Drogasil has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's 12-1 Month Momentum % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #123 out of 656 companies for 12-1 Month Momentum %. This places Raia Drogasil in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Healthcare Providers & Services company?
A good 12-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Raia Drogasil and its competitors. Raia Drogasil's current 12-1 Month Momentum % is 18.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$27.42, compared to a current price of R$19.99 — trading 27.1% below its estimated fair value. The current 12-1 Month Momentum % is 18.87%. Raia Drogasil's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current 12-1 Month Momentum % is 18.87% as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$19.99 is trading 27.1% below its estimated GF Value™ of R$27.42.
GuruFocus considers Raia Drogasil to be Modestly Undervalued.
Key valuation signals for BSP:RADL3:
12-1 Month Momentum %: 18.87%
GF Value™: R$27.42 vs. price of R$19.99 (27.1% below fair value)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
95GF Score
Get the complete analysis for BSP:RADL3
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
